Although aspirin has been recently focused on for its antitumor effects, especially for CRC patients bearing PIK3CA mutations, which are expected to be a predictive marker to stratify responders to aspirin treatment [5], we first clarified aspirin-mediated metabolic perturbation of glutaminolysis, which may be targetable to further sensitize PIK3CA-mutated cells to aspirin. This evidence concerns the gene PIK3CA and colorectal carcinoma.